symbol,statement_type,period_end,line_item,value
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.34055
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Normalized EBITDA,120638000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Total Unusual Items,0.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,19449000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,4620612000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,EBITDA,120638000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,EBIT,101189000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Interest Income,-40170000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Interest Expense,40170000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Interest Income,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Normalized Income,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Total Expenses,4736368000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Diluted Average Shares,28139161.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Basic Average Shares,28139161.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Diluted EPS,1.43
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Basic EPS,1.43
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income Discontinuous Operations,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,40239000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Tax Provision,20780000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Pretax Income,61019000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,98124000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Special Income Charges,0.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Write Off,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-40170000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,40170000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Operating Income,3065000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Operating Expense,115756000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Other Operating Expenses,54595000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,19449000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,19449000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Selling General And Administration,33657000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,23911000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,General And Administrative Expense,9746000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Gross Profit,118821000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Cost Of Revenue,4620612000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Total Revenue,4739433000.0
AAREYDRUGS.NS,income,2025-03-31 00:00:00,Operating Revenue,4739433000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.123397
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Normalized EBITDA,114162000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Total Unusual Items,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,16980000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,3818986000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,EBITDA,114162000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,EBIT,97182000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Interest Income,-43753000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Interest Expense,43753000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Interest Income,48735000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Normalized Income,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Total Expenses,3928646000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,5323000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Diluted Average Shares,25454891.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Basic Average Shares,25454891.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Diluted EPS,1.84
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Basic EPS,1.84
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income,46837000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,46836000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income Discontinuous Operations,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,46836000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Tax Provision,6593000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Pretax Income,53429000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,69649000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Special Income Charges,0.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Write Off,189000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-43753000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,653000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,43753000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,48735000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Operating Income,27533000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Operating Expense,109660000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Other Operating Expenses,62669000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,16980000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,16980000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Selling General And Administration,22827000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,11910000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,General And Administrative Expense,10917000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,5323000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Gross Profit,137193000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Cost Of Revenue,3818986000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Total Revenue,3956179000.0
AAREYDRUGS.NS,income,2024-03-31 00:00:00,Operating Revenue,3956179000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-169861.821086
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.372504
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Normalized EBITDA,102397000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Total Unusual Items,-456000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-456000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,37711000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,15738000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,4038407000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,EBITDA,101941000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,EBIT,86203000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Interest Income,-2953000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Interest Expense,26107000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Interest Income,26331000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Normalized Income,37997138.178914
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,37711000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Total Expenses,4108451000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,4879000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Diluted Average Shares,25385000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Basic Average Shares,25385000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Diluted EPS,1.49
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Basic EPS,1.49
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,37711000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,37711000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income,37711000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,37710000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income Discontinuous Operations,0.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,37710000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Tax Provision,22386000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Pretax Income,60096000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,47995000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Special Income Charges,-456000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Write Off,456000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-2953000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,3177000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,26107000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,26331000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Operating Income,20047000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Operating Expense,70044000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Other Operating Expenses,33846000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,15738000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,15738000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Selling General And Administration,6979000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,2559000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,General And Administrative Expense,4420000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,4879000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Gross Profit,90091000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Cost Of Revenue,4038407000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Total Revenue,4128498000.0
AAREYDRUGS.NS,income,2023-03-31 00:00:00,Operating Revenue,4128498000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-150226.25061
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.346943
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Normalized EBITDA,139810000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Total Unusual Items,-433000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-433000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,19883000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,4720549000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,EBITDA,139377000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,EBIT,119494000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Interest Income,-311000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Interest Expense,19123000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Interest Income,20086000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Normalized Income,65830773.74939
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Total Expenses,4821222000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,6823000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Diluted Average Shares,24075000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Basic Average Shares,24075000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Diluted EPS,2.72
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Basic EPS,2.72
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income Discontinuous Operations,0.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,65548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Tax Provision,34823000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Pretax Income,100371000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,5848000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Special Income Charges,-433000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Write Off,433000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-311000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,1274000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,19123000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,20086000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Operating Income,94875000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Operating Expense,100673000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Other Operating Expenses,54189000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,19883000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,19883000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Selling General And Administration,10028000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,3891000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,General And Administrative Expense,6137000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,6823000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Gross Profit,195548000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Cost Of Revenue,4720549000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Total Revenue,4916097000.0
AAREYDRUGS.NS,income,2022-03-31 00:00:00,Operating Revenue,4916097000.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Total Unusual Items,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,EBITDA,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,EBIT,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Interest Income,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Interest Expense,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Interest Income,24287607.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Normalized Income,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Total Expenses,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,6697720.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Basic Average Shares,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Diluted EPS,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Basic EPS,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income Discontinuous Operations,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Tax Provision,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Pretax Income,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Special Income Charges,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Write Off,0.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,1133881.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,24287607.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Operating Income,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Operating Expense,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Selling General And Administration,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,General And Administrative Expense,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,6697720.0
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Gross Profit,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Total Revenue,
AAREYDRUGS.NS,income,2021-03-31 00:00:00,Operating Revenue,
